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Abstract
Endoscopic retrograde cholangiopancreatography 
(ERCP) is the essential first modality for common bile 
duct (CBD) stone therapy. The conventional endoscopic 
treatment for CBD stones is stone removal after en-
doscopic sphincterotomy (EST). Stone removal after 
papillary stretching using balloon dilation instead of 
the conventional method has been widely adopted. 
There are many reports regarding endoscopic papil-
lary balloon dilation (EPBD) utilizing a small balloon (< 
10 mm) instead of EST for the removal of small CBD 
stones. In contrast, two cases of mortality due to post-
ERCP pancreatitis (PEP) were reported after an EPBD 
clinical trial in the Western world, and the psychological 
barrier caused by these incidences hinders the use of 
this technique in Western countries. Endoscopic papillar 
large balloon dilation (EPLBD), which is used to treat 
large CBD stones, was not widely adopted when first 
introduced due to concerns about perforation and se-
vere pancreatitis from the use of a large balloon (12-20 
mm). However, as experience with this procedure ac-
cumulates, the occurrence of PEP with EPLBD is con-
firmed to be much lower than with EPBD. This report 
reviews whether EPBD and EPLBD, two procedures that 
use balloon dilation but differ in terms of indications 
and concept, contribute to the occurrence of PEP.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Endoscopic papillary balloon dilation (EPBD) 
and endoscopic papillary large balloon dilation (EPLBD) 
have been performed for removal of common bile duct 
stones. Although the rates of post-endoscopic retro-
grade cholangiopanc- reatography pancreatitis (PEP) 
after EPBD and EPLBD varied in many studies, the safe-
ty and feasibility of balloon dilation have been proven 
as results have accumulated. However, the exact mech-
anism of PEP after balloon dilation is unclear. The main 
determinant of severe PEP may be edema or spasm 
caused by irritation of the pancreatic orifice while per-
forming difficult selective cannulation and struggling to 
remove the stone rather than balloon compression of 
the pancreatic flow.
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INTRODUCTION
Post-endoscopic retrograde cholangiopancreatography 
(ERCP) pancreatitis (PEP) is a complicating adverse 
event, for which doctors can do little to treat. Removing 
common bile duct (CBD) stones is the most frequently 
performed procedure carried out using ERCP. Conven-
tional endoscopic biliary stone removal through endo-
scopic sphincterotomy (EST) has been replaced by the 
balloon dilation method.
PEP, the most common and potentially serious com-
plication of  ERCP-related procedures, occurs in 1%-9% 
of  all procedures[1]. Many studies of  the risk and predic-
tive factors to prevent PEP have been conducted[1-16]. To 
discuss the risk factors for PEP, not only procedural and 
technical factors but also patient characteristics should 
be considered[1,15]. Patient-related factors for PEP include 
a history of  post-ERCP pancreatitis[1,9,10,12,16,17], female 
sex[1,10,15], young age[3,4,6,12,15], suspected sphincter of  Oddi 
dysfunction (SOD)[1,2,4,10,12,14], and absence of  chronic pan-
creatitis[1]. Procedural-related factors include difficult can-
nulation[1,9,15-17], precut sphincterotomy[2,10,15,16], pancreatic 
deep wire pass[15], pancreatic sphincterotomy[1], pancreatic 
contrast injections[1-4,10,12,17,18], and biliary balloon sphincter 
dilation[1]. These reported risk factors vary among stud-
ies, and some contradict each other. Hence, the data for 
risk factors for PEP should be interpreted with caution. 
Such discrepancies may have arisen from heterogeneous 
patient populations or from differences in the level of  
endoscopic expertise, cannulation techniques, and defini-
tion of  post-ERCP pancreatitis[12]. 
The PEP mechanism is not well defined, but it is 
commonly accepted to be multifactorial, involving me-
chanical, chemical, hydrostatic, enzymatic, microbial, 
and thermal factors[1,12]. A certain triggering event may 
prematurely activate proteolytic enzymes intracellularly 
within acinar cells, which may cause cellular injury and 
autodigestion of  pancreatic tissue[19,20]. Various PEP 
mechanisms have been suggested. PEP may occur from 
incidental injection of  contrast medium into the pancre-
atic duct in cases where cannulation of  the bile duct is 
difficult; in such cases, the type of  contrast medium in-
jected and the speed and pressure of  injection leading to 
complete acinar filling of  the pancreas can have an influ-
ence[8,21-23]. Hydrostatic injury caused by pancreatic duct 
overfilling may be a major trigger factor for pancreatic 
reactions[16]. Difficult cannulation may inflict trauma to 
the papilla and pancreatic sphincter, leading to pancreatic 
drainage disruption and causing PEP[12,24,25]. Pancreatitis 
after pancreatic sphincterotomy, and precutting have 
been discussed based on the possibility of  incidental tem-
porary obstruction of  the pancreatic duct, caused by di-
rect thermal damage to the duct by the cutting wire or by 
edema induced by thermal tissue injury[8,26]. PEP occurs 
more frequently in patients with SOD[1,2,10,14,24,27-29], which 
may cause a flow disturbance in pancreatic drainage due 
to pancreatic sphincter hypertension. 
Balloon inflation is also a possible cause of  PEP. The 
pancreatic orifice is compressed during ballooning, and 
pancreatic flow is transiently disrupted. However, it is un-
known whether ballooning itself  is a major determinant 
for the development of  PEP due to endoscopic papil-
lary balloon dilation (EPBD) and endoscopic papillary 
large balloon dilation (EPLBD). This report provides a 
systemic review of  how the balloon itself  affects PEP in 
balloon dilation during EPBD and EPLBD.
ENDOSCOPIC PAPILLARY BALLOON 
DILATION AND ENDOSCOPIC PAPILLARY 
LARGE BALLOON DILATION
Definition and concepts
The ampullary orifice and distal CBD are dilated tem-
porarily by balloon dilation during EPBD and EPLBD 
procedures. However, EPBD and EPLBD are not the 
same procedure in either concept or indications. EPBD 
is performed in patients with a non- or minimally dilated 
CBD[30]. In contrast, EPLBD should be performed in pa-
tients with dilated CBD and ampulla due to a large long-
standing stone. Ballooning of  the CBD and ampullary 
orifice stretches the tissue transiently to form a tubular 
shape to facilitate stone removal. In this process, suc-
cessful dilation depends on the elasticity, the degree of  
dilation of  the CBD tissue, and the absence of  stricture. 
Moreover, the ease of  selective bile duct cannulation and 
stone removal through the widened ampullary orifice 
might be associated with the occurrence of  PEP. 
EPBD has been performed to dilate the biliary 
sphincter without prior EST by using a small-diameter 
dilating balloon (≤ 10 mm). EPBD can avoid the short-
term complications of  bleeding and perforation, preserve 
the function of  the biliary sphincter, and reduce long-
term sequelae of  EST. Additionally, EPLBD has been 
used to remove large CBD stones after dilating the biliary 
sphincter with EST using a large-diameter dilation (≥ 12 
mm). EPLBD can reduce the use of  mechanical litho-
tripsy (MLT), thereby avoiding complications related to 
the use of  full EST for the removal of  large or difficult 
CBD stones. The majority of  EPLBDs involve limited 
EST (minimal or mid-EST rather than full EST) followed 
by large balloon inflation. If  EST is performed toward 
the CBD, tearing advances in the same direction[31]. This 
combined approach does not require full EST and can 
enlarge the biliary orifice to a greater extent than a stan-
dard full EST[30]. 
Indications
EPBD is a possible alternative to EST in patients with 
impaired hemostasis[11]. To maximize the effect of  EPBD 
while minimizing complications, a technique with proper 
indication and in the proper manner is necessary[32]. 
Recommended indications for balloon dilation include 
coagulopathy, periampullary diverticulum, Billroth II 
gastrojejunostomy, and prior EST status[32]. Another 
study suggested that the ideal patients are those with a 
limited number of  CBD stones (≤ 3), CBD stones of  a 
maximum diameter ≤ 10 mm, and minimally dilated bile 
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duct[33]. In addition, in cases with difficult cannulation, 
impractical cannulation should be avoided. The use of  
EPBD for removing CBD stones > 10 mm may neces-
sitate a laborious and papilla-traumatic procedure, such as 
MLT, and may increase the risk of  pancreatitis[34]. EPBD 
for a large CBD stone requires multiple sessions and is 
time-consuming because the biliary orifice is not dilated 
sufficiently[35]. Therefore, relatively large stones with a 
non-dilated CBD are not good candidates for EPBD. 
Further large-scale studies with a longer follow-up are 
imperative to identify more distinct indications and the 
optimum method.
Strict indications are needed for EPLBD to avoid 
serious adverse events. The patients suitable for this 
method are those who already have a dilated CBD due to 
a large stone[36]. The tissue of  ampulla and distal CBD in 
these patients are ready to be dilated and further gradual 
stretching of  the tissue will not cause stress or sudden 
tearing of  the ampullary roof. However, patients with 
the CBD of  less than the balloon size or strictures of  the 
distal CBD should be excluded because of  the possibil-
ity of  perforation. The velocity and duration of  balloon 
inflation vary across studies, ranging from a few seconds 
to minutes. Although guidelines pertaining to the optimal 
velocity of  balloon inflation have yet to be established, 
the following guidelines for safe EPLBD were proposed 
based on the current knowledge[36,37]: (1) selection of  
suitable candidates; i.e., EPLBD should be reserved for 
patients with a dilated CBD, but avoided in patients with 
distal CBD strictures; (2) avoidance of  full-EST immedi-
ately before large balloon dilation to prevent perforation 
and bleeding; (3) gradual inflation of  the dilating balloon 
to recognize a narrowed distal CBD indicated by lack of  
disappearance of  the balloon waist; (4) discontinuation of  
inflation when resistance is encountered in the presence 
of  a persistent balloon waist; (5) not inflating the dilation 
balloon beyond the maximal size of  the upstream dilated 
CBD; and (6) conversion to alternative stone removal or 
drainage methods when difficulty in removal of  a stone 
is encountered. When a tapered, distal CBD or occult 
stricture is identified, the operator should pay particular 
attention to avoiding fatal adverse events caused by large 
perforations occurring during balloon inflation.
BALLOONING AND PEP
Acute pancreatitis after endoscopic papillary balloon 
dilation
EPBD, suggested by Staritz et al[38], is an alternative 
method to EST for removal of  CBD stones. EPBD 
was adopted to reduce the risk of  bleeding[39-42] and 
preserve the function of  the sphincter of  Oddi[40,43-47]. 
Some studies have reported that there was no differ-
ence in efficacy and safety between EST and EPBD[46,48], 
whereas others claimed that the incidence of  pancreatitis 
was higher among patients who received EPBD com-
pared with those who received EST[33,49,50]. The results 
of  randomized control studies comparing EPBD and 
EST are inconsistent, particularly in terms of  the inci-
dence and severity of  PEP[46,48-50]. Severe morbidity in 
the EPBD group compared with the EST group caused 
early termination of  one study[51], and some clinicians as-
sert that EPBD should not be performed based on the 
pancreatitis-induced mortality that occurred during some 
studies[50,52]. In particular, another randomized, controlled 
multicenter trial was also terminated early during the first 
interim analysis, because two patients died from severe 
pancreatitis as a complication of  EPBD[50]. Thus, the in-
vestigation of  risk factors for EPBD-related pancreatitis 
remains controversial.
In studies from Holland[46] and the United King-
dom[48], the incidence rates of  pancreatitis with EPBD 
appeared to be similar to those with EST. In a Japanese 
study, the pancreatitis rate was slightly higher with EPBD 
than with EST[49]. In contrast, an American study by 
Disario et al[50] reported that the post-EPBD pancreatitis 
rate was higher than that of  EST, and mortality was due 
to pancreatitis. Although EPBD is used less frequently in 
Western countries due to these complications, it has been 
continuously adopted in some Japanese groups. There 
is no clear explanation for this discrepancy, but it is pre-
sumed that differences in patient populations and meth-
ods of  balloon dilation may play a role[42]. In addition, the 
US study may have included patients with SOD[42]. Thus, 
pancreatitis-associated EPBD is a very controversial and 
serious topic[53,54]. 
The incidence of  acute pancreatitis after EPBD rang-
es from 5%-20%, although most figures fall in the range 
of  5%-7%[43,46,51]. The frequency and severity of  PEP 
following EPBD are summarized in Table 1. The precise 
mechanism underlying post-EPBD pancreatitis is not 
well defined, and appears to be multifactorial. Contrast 
medium injection into the pancreatic duct[11] and a history 
of  prior pancreatitis[54] are suggested to be risk factors for 
post-EPBD pancreatitis. Younger age is a risk factor for 
post-ERCP pancreatitis[3,4,6,12,15], but not for post-EPBD 
pancreatitis[11,54]. However, in real practice, most cases of  
severe pancreatitis involve relatively young patients with 
unatrophied pancreatic tissue.
The mechanism of  pancreatitis induced by superflu-
ous injection of  contrast medium is regarded as the same 
as that with EST[11]. Some research suggests that papillary 
edema or spasm caused by balloon dilation can result in 
pancreatitis by obstructing pancreatic outflow[11,42]. Bal-
loon compression of  the papilla or the pancreatic duct 
orifice may provoke peripapillary edema and/or spasm 
of  the sphincter of  Oddi[51,53]. However, peripapillary 
trauma by cannulation can more definitely and frequently 
provoke spasm of  the sphincter of  Oddi and/or hem-
orrhagic edematous change[55], and it is a potential risk 
factor for asymptomatic hyperamylasemia after EPBD[54]. 
In addition, the biliary orifice may not fully dilate during 
stone removal with EPBD[56,57]. In this situation, stone 
removal can be more technically challenging and time-
consuming[46,50,58], and subsequent papillary injury or 
edema during stone extraction can cause pancreatitis[35]. 
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Acute pancreatitis after endoscopic papillary large 
balloon dilation with EST
EPLBD with limited EST is gradually being recognized 
as an important modality for the removal of  large CBD 
stones[36,59-67]. Pancreatitis occurs in 2.4% (0%-13.2%) of  
In particular, stone removal by EPBD becomes more dif-
ficult when the stone is large and the use of  MLT is more 
frequent[33,50]. In such cases, the biliary orifice is more 
likely to be damaged, and the risk of  pancreatitis can be 
greater.
Table 1  Frequency and severity of pancreatitis and complications after endoscopic papillary balloon dilation
Ref. Study 
design
Study’s 
location
Comparison 
groups (n )
Pancreatitis 
n  (%)
Pancreatitis severity (n ) Other complications (n ) Overall 
AEs-related 
death (n)
Mild/
moderate
Severe Death Bleeding Perforation Cholangitis
Minami et al[85], 
(1995)
RCT Japan EPBD (n = 20)    2 (10)   2 0 0   0 0   0 0
EST (n = 20)    2 (10)   2 0 0   0 0   0 0
Mathuna et al[86], 
(1995)
R Ireland EPBD 
(n = 100)
    5 (4.8)   5 0 0   0 0   0 0
Bergman et al[46], 
(1997)
RCT The 
Netherlands
EPBD 
(n = 101)
    7 (6.9)   5 2 0   0 2   0 0
EST (n = 101)     7 (6.9)   6 1 0   4 1   0 1
Yasuda et al[87], 
(1998)
P Japan EPBD (n = 92)     8 (8.7)   8 0 0   0 0   0 0
Ueno et al[55], 
(1999)
R Japan EPBD 
(n = 109)
    21 (19.8) 21 0 0 NA NA NA 0
Ochi et al[88], 
(1999)
RCT Japan EPBD (n = 55) 0   0 0 0   0 0   0 0
EST (n = 55)    2 (3.6)   2 0 0   0 1   0 0
Arnold et al[51], 
(2001)
RCT Germany EPBD (n = 30)      6 (20.0)   4 2 0   0 0   3 0
EST (n = 30)      3 (10.0)   3 0 0   2 0   0 0
Bergman et al[53], 
(2001)
RCT The 
Netherlands
EPBD (n = 93)    7 (7.5)   5 2 0   0 2   0 1
EST (n = 87)    7 (8.0)   6 1 0   2 0   0 0
Yasuda et al[43], 
(2001)
RCT Japan EPBD (n = 35)    2 (5.7)   2 0 0   0 0   0 0
EST (n = 35)    2 (5.7)   2 0 0   1 0   0 0
Natsui et al[89], 
(2002)
RCT Japan EPBD (n = 70)    4 (5.7)   4 0 0   0 0   2
EST (n = 70)    3 (4.3)   3 0 0   2 0   3
Fujita et al[49], 
(2003)
RCT Japan EPBD 
(n = 138)
   15 (10.9) 15 0 0   0 0   2 0
EST (n = 144)    4 (2.7)   4 0 0   2 0   6 0
Vlavianos et al[48], 
(2003)
RCT United 
Kindom
EPBD 
(n = 103)
   5 (4.9)   4 1 0   0 0   2 0
EST (n = 99)    1 (1.0)   1 0 0   0 0   1 1
Sugiyama et al[54], 
(2003)
R Japan EPBD 
(n = 118)
   7 (6.0)   7 0 0   0 0   0 0
Lin et al[90], 
(2004)
RCT Taiwan EPBD (n = 51) 0   0 0 0   1 0   0 0
EST (n = 53) 0   0 0 0 14 0   0 0
Disario et al[50], 
(2004)
RCT United 
States
EPBD 
(n = 117)
   18 (15.4) 12 6 2 11 0   1 2
EST (n = 120)    1 (0.8)   1 0 0 32 1   1 0
Tanake et al[91], 
(2004)
RCT Japan EPBD (n = 16)      3 (18.8)   1 2 0   0 0   0 0
EST (n = 16)      3 (18.8)   2 1 0   0 0   2 0
Toda et al[92], 
(2005)
RCT Japan EPBD (n = 94)    7 (6.4)   7 0 0   0 0   4 0
EST (n = 102) 3 (3)   3 0 0   2 2   4 0
Tsujino et al[11], 
(2005)
R Japan EPBD 
(n = 304)
 15 (5.0) 15 0 0   0 1   6 0
Nakagawa et al[93], 
(2006)
R Japan EPBD 
(n = 201)
   2 (1.0)   0 2 0   0 0   3 0
Tsujino et al[42], 
(2007)
P Japan EPBD 
(n = 1000)
 48 (4.8) 47 1 0   2 2 27 2
Ito et al[35], 
(2008)
R Japan EPBD 
(n = 406)
 19 (5.7) 19 0 0   0 1   4 0
Liao et al[94], 
(2008)
RCT Taiwan EPBD (n = 35)    2 (5.7)   2 0 0   0 0   1 0
EST (n = 25)   3 (12)   3 0 0   2 0   2 0
Natsui et al[95], 
(2011)
RCT Japan EPBD (n = 41)    2 (4.8)   2 0 0   0 0   1 0
EST (n = 42)    1 (2.3)   1 0 0   0 0   1 0
Kuo et al[96], 
(2012)
R Taiwan EPBD 
(n = 273)
   30 (10.1) 22 8 0   1 1   9 1
Seo et al[97], 
(2014)
RCT South Korea EPBD (n = 62)    5 (8.1)   5 0 0   0 0   0 0
EST (n = 70)    5 (7.1)   5 0 0   2 1   0 0
EST: Endoscopic sphincterotomy; AEs: Adverse events; EPBD: Endoscopic papillary balloon dilation; R: Retrospective; P: Prospective; RCT: Randomized 
controlled trial; NA: Not available.
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patients; almost all cases have been of  mild to moder-
ate severity (98.4%)[37,68,69]. The frequency and severity of  
PEP after EPLBD with EST are summarized in Table 2. 
Standard procedural guidelines have not been estab-
lished; yet, most procedures involve limited EST followed 
by large balloon inflation. If  EST is performed toward 
the CBD, the direction of  tearing advances toward the 
CBD, and less pressure is applied on the pancreatic 
duct[31]. It has been suggested that the radial force gener-
ated by the dilating balloon is exerted toward the CBD 
and moves away from the pancreatic duct, which lessens 
the likelihood of  pancreatitis by reducing periampullary 
injury[31,36,37,62,70]. Moreover, and in contrast to EPBD, 
EPLBD dilates the ampullary orifice sufficiently to al-
low for straightforward removal of  a large CBD stone, 
using a Dormia basket or retrieval balloon, and so that it 
is wide enough to reduce the need for MLT[71]. Addition-
ally, because of  the patulous papillary orifice caused by a 
large stone, endoscopists feel comfortable with selective 
cannulation of  the bile duct in most patients. These are 
all reasons for decreased occurrence of  pancreatitis by 
reduced ampulla injury, which can cause periempullary 
trauma or edema[36]. 
Surprisingly, according to a multicenter retrospective 
study[37], there was no severe PEP after EPLBD among 
946 patients. This provides strong evidence that balloon-
ing itself  is not a major determinant of  PEP in EPLBD. 
Moreover, according to a systemic review of  EPLBD, 
even though the inclusion criteria and procedure type 
were heterogeneous[69], PEP following EPLBD was not 
problematic. The duration of  ballooning in EPLBD is 
usually 30-60 s in real practice. However, the timing of  
balloon inflation is not related to PEP[30,69], so prolonged 
balloon inflation does not increase PEP in EPLBD.
Acute pancreatitis after EPLBD without EST
EPLBD without EST is preferred in patients with bleed-
ing tendencies, altered anatomy, and, in some cases, 
periampullary diverticulum[34]. If  EST is not performed 
prior to balloon application, theoretically, the PEP rate 
may increase because pancreatic outflow could be more 
completely obstructed by the balloon. In addition, the 
balloon could press the pancreatic orifice from a more 
acute angle than when the papillary roof  incision is made, 
because the biliary and pancreatic orifices are not sepa-
rated. However, according to a retrospective analysis[30] 
and systematic review[69], the PEP rate is not high and 
does not differ between EPLBD with and without EST. 
Moreover, the incidence of  PEP did not change with bal-
looning time[68]. Therefore, ballooning during EPLBD is 
not a major factor for PEP, regardless of  whether EST is 
performed.
Some recent studies have reported that EPLBD with-
out EST is safe and effective in patients with large CBD 
stones[34,72,73]. Pancreatitis and bleeding occurred at a rate 
of  0.8%-6.5%, and all cases were of  mild to moderate se-
verity. The frequency and severity of  PEP after EPLBD 
without EST are summarized in Table 3. This is sup-
ported by a large-scale study reporting less frequent pan-
creatitis resulting from a larger balloon[37]. In other words, 
the extent of  biliary orifice dilation is relevant to the inci-
dence of  pancreatitis, rather than the size of  the balloon, 
EST performance, or balloon dilation time[65,68,73]. 
DISCUSSION
Although EPBD involves a high incidence of  pancreati-
tis, the reports are inconsistent, and it remains controver-
sial. In studies with high rates of  pancreatitis, a discrep-
ancy in patient selection should have been made before 
suggesting balloon dilation as the primary risk factor for 
pancreatitis. The reason for the high incidence of  pancre-
atitis in EPBD is that enables removal of  only small-to-
medium sized stones, and patients with such a stone size 
tend to possess the known risk factors for pancreatitis: 
young age, non-dilated CBD, normal pancreas paren-
chyma, obesity, and SOD dysfunction. In other words, 
careful patient selection can lessen the risk of  post-ERCP 
pancreatitis. EPBD for larger CBD stones, rather than a 
non-dilated CBD, requires multiple sessions and is more 
time consuming for stone removal than EST, because 
EPBD cannot dilate the biliary orifice sufficiently[35]. 
Baron et al[33] recommended extreme caution when per-
forming EBPD in patients with severe acute cholangitis, 
a history of  previous or ongoing acute pancreatitis, age 
≤ 50 years, and difficult biliary cannulation. To prevent 
post-ERCP pancreatitis, pancreatic duct stent insertion is 
also recommended when EPBD is performed in young 
patients[33]. 
The frequency or severity of  PEP after EPBD did 
not vary with ballooning time. This implies that balloon 
compression of  the pancreatic orifice for < 1 or 2 min 
without stimulated pancreatic secretion does not cause 
significant pancreatitis. In one randomized prospective 
study[74], 5-min EPBD reduced the risk of  pancreatitis 
compared with conventional 1-min EPBD. Rather than 
ballooning itself, we believe that pancreatic edema or 
spasm caused by papillary irritation due to difficult selec-
tive cannulation and forcible stone extraction might be 
the major determinant of  PEP after EPBD.
During the early period of  EPLBD, PEP is the main 
concern, because the pancreatic orifice is compressed 
with a balloon larger than that used in EPBD. However, 
accumulated data inform clinicians that the larger balloon 
does not result in PEP, although in practice, one case of  
severe pancreatitis with mortality has been reported[75]. 
Although the major etiological factors of  pancreatitis and 
its mechanism remain unclear, the mechanism of  pancre-
atitis may differ between EPLBD and EPBD. EPLBD 
and EPBD are different procedures clinically. The major 
difference is that EPLBD cannot be applied to a non-
dilated bile duct, which can be a risk factor for PEP[54]. If  
the orifice is sufficiently dilated by EPLBD, papillary ede-
ma or spasm is less likely to occur due to use of  a basket 
or retrieval balloon catheter, unlike EPBD, and the inci-
dence of  pancreatitis may decline due to the less frequent 
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Table 2  Frequency and severity of pancreatitis and complications after endoscopic papillary large balloon dilation with endoscopic 
sphincterotomy
Ref. Study 
design
Study’s 
location
Comparison 
groups (n )
Balloon 
diameter 
(mm)
Pancreatitis
n  (%)
Pancreatitis severity (n ) Other complications (n ) Overall 
AEs-related 
death (n)
Mild/
moderate
Severe death Bleeding Perforation Cholangitis
Ersoz et al[31], 
(2003)
R Turkey EPLBD 
(n = 58)
12-20    2 (3.4) 2 0 0 5 0 2 0
Maydeo et al[60], 
(2007)
P India EPLBD 
(n = 60)
12-20 0 (0) 0 0 0 5 0 0 0
Minami et al[62], 
(2007)
R Japan EPLBD 
(n = 88)
20    1 (1.1) 1 0 0 1 0 1 0
Heo et al[61], 
(2007)
RCT South 
Korea
EPLBD 
(n = 100)
12-20    4 (4.0) 4 0 0 0 0 0 0
EST 
(n = 100)
-    4 (4.0) 4 0 0 2 0 0 0
Lee et al[98], 
(2007)
R South 
Korea
EPLBD 
(n = 55)
15-20 0 (0) 0 0 0 2 0 0 0
Kim et al[99], 
(2007)
R South 
Korea
EPLBD 
(n = 35)
12-20 0 (0) 0 0 0 0 1 0 0
Lee et al[100], 
(2007)
R South 
Korea
EPLBD 
(n = 41)
13-20    2 (4.8) 0 0 0 1 0 0 0
Misra et al[101], 
(2008)
R India EPLBD 
(n = 50)
15-20    4 (8.0) 4 0 0 3 0 0 0
Attasaranya et 
al[63], (2008)
R United 
States
EPLBD 
(n = 103)
12-18 0 (0) 0 0 0 2 1 0 0
Espinel et al[102], 
(2008)
P Spain EPLBD 
(n = 93)
12-20    1 (1.1) 1 0 0 1 0 0 0
Itoi et al[103], 
(2009)
R Japan EPLBD 
(n = 53)
15-20    1 (1.9) 1 0 0 0 0 1 0
EST (n = 48) -    2 (4.1) 2 0 0 0 0 1 0
Kim et al[104], 
(2009)
RCT South 
Korea
EPLBD 
(n = 27)
15-18 0 (0) 0 0 0 4 0 0 0
EST (n = 28) - 0 (0) 0 0 0 2 0 0 0
Itoi et al[105], 
(2010)
R Japan EPLBD 
(n = 18)
15-18 0 (0) 0 0 0 0 0 0 0
Kurita et al[106], 
(2010)
R Japan EPLBD 
(n = 24)
15-20 0 (0) 0 0 0 0 0 0 0
Ghazanfar et al[107], 
(2010)
P Pakistan EPLBD 
(n = 84)
15-18    3 (3.6) 3 0 0 3 0 0 1
Kim et al[108], 
(2010)
R South 
Korea
EPLBD 
(n = 70)
12-18    1 (2.3) 1 0 0 0 0 0 0
Youn et al[65], 
(2011)
R South 
Korea
EPLBD 
(n = 101)
15-20    2 (2.0) 2 0 0 2 1 0 0
Kim et al[109], 
(2011)
R South 
Korea
EPLBD 
(n = 72)
12-20    5 (6.9) 5 0 0 0 0 1 0
EST (n = 77) -      9 (11.7) 9 0 0 0 1 0 0
Stefanidis et al[75], 
(2011)
RCT Greece EPLBD 
(n = 45)
15-20    1 (2.2) 1 0 0 1 0 0 0
EST (n = 45) -    1 (2.2) 1 0 0 1 1 6 0
Rebelo et al[67], 
(2012)
R Portugal EPLBD 
(n = 30)
12-18    1 (3.3) 1 0 0 0 0 0 0
Sakai et al[110], 
(2013)
R Japan EPLBD 
(n = 59)
12-20 0 (0) 0 0 0 1 1 0 0
Park et al[37], 
(2013)
R South 
Korea, 
Japan
EPLBD 
(n = 946)
12-20    24 (25.3)       24 0 0      56 9 6 4
Poincloux et al[64], 
(2013)
R France EPLBD 
(n = 64)
15-20    2 (3.1) 2 0 0 5 0 0 0
Hwang et al[73], 
(2013)
R South 
Korea
EPLBD 
(n = 69)
12-20    3 (4.3) 3 0 0 0 1 0 0
Paspatis et al[68], 
(2013)
RCT Greece 60 s 
dilation1 
(n = 60)
15-20    2 (1.6) 2 0 0 4 1 3 0
30 s 
dilation1 
(n = 64)
15-20    2 (1.6) 1 1 1 2 1 2 1
Rosa et al[66], 
(2013)
R Portugal EPLBD 
(n = 68)
12-18      9 (13.2) 9 0 0 0 0 1 0
EST (n = 45) -    2 (4.7) 2 0 0 0 0 1 0
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use of  MLT[34,72]. There is no significant difference in the 
frequency of  the requirement for MLT between EPLBD 
and the conventional method. However, adequate frag-
mentation of  the CBD stone by MLT after EPLBD can 
reduce the frequency of  the requirement for MLT in 
EPLBD compared with the conventional method[69]. This 
could be one reason for the lower incidence of  PEP in 
EPLBD. Patients who receive EPLBD are relatively older 
individuals in whom pancreatic exocrine function has 
declined, and pancreatitis is less likely[72]. Further, easy 
selective cannulation into the bile duct can reduce the in-
cidence of  pancreatitis. Additionally, contrary to our con-
cern, EPLBD without a preceding papillary incision did 
not cause severe pancreatitis[34,72,73]. Therefore, ballooning 
itself  may not be the culprit. And the cause of  fatal pan-
creatitis during EPBD should be reconsidered.
The incidence of  pancreatitis, using percutaneous 
papillary balloon dilation (PTPBD) for CBD stone re-
moval, is extremely low (0%-1.4%)[76-82]. A retrospective 
study reported that pancreatitis occurred only in the 
EPBD group; in another study, comparing PTPBD with 
EPBD, the only significant predictor was the use of  
MLT[76]. The size of  the balloon used in PTPBD varies 
(4-23 mm) among studies and can also vary within the 
same study, due to the presence of  differently sized CBD 
stones (5-20 mm)[77-82]. In one study[76], patients with a 
CBD stone < 12 mm in diameter were enrolled homog-
enously, and the balloon dilation diameter was 8-10 mm, 
which was compatible with EPBD. The largest balloons 
used for papillary dilation were of  diameters 22 mm[80] 
and 23 mm[82] in other studies; this balloon inflation size 
is compatible with EPLBD. Although the balloon dilation 
diameter was different in each study, no severe pancre-
atitis occurred. These studies confirmed that ballooning 
does not increase the incidence of  PEP. Moreover, the 
rates of  post-procedural pancreatitis and hyperamylas-
emia were significantly higher following retrograde dila-
tion using EPBD, compared with antegrade dilation using 
PTPBD, during the removal of  bile duct stones[76].
The reason for the lower rate of  PEP with ante-
grade application of  balloon inflation compared with 
a retrograde fashion is the lack of  difficulty in selective 
cannulation and lower chance of  difficult procedure for 
forcible removal unless the stone descends. Compared 
with EPBD, PTPBD inflicts less mechanical trauma to 
papilla during stone removal, and it is nearly equivalent to 
the effect of  ballooning[83,84]. In addition, MLT applica-
tion does not involve lithotripsy moving back and forth 
through the ampullary orifice, in which there is no chance 
of  pancreatic orifice damage. Such a result demonstrates 
that ballooning may not be a risk factor for pancreatitis. 
Moreover, the rates of  post-procedural pancreatitis and 
hyperamylasemia were significantly higher after retro-
grade dilation with EPBD than after antegrade dilation 
with PTPBD for the removal of  bile duct stones. This 
reveals that pancreatitis can be induced by other factors, 
such as repeated cannulation or pancreatic duct injection, 
during retrograde dilation with EPBD.
CONCLUSION
Although the mechanism of  PEP is unclear, the occur-
rence of  pancreatitis is more associated with the catheter, 
basket, or MLT causing ampullary injury. Instead of  bal-
loon compression of  the pancreatic flow, the main deter-
minants of  severe pancreatitis during endoscopic stone 
removal with balloon dilation may involve edema or 
spasm caused by irritation of  the pancreatic orifice while 
performing difficult selective cannulation and struggling 
to remove the stone. Therefore, ballooning itself  may not 
be the culprit for PEP in either EPBD or EPLBD.
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